About Lengo Therapeutics
Lengo Therapeutics is a company based in San Diego (United States) founded in 2020 was acquired by Blueprint Medicines in November 2021.. Lengo Therapeutics has raised $15 million across 1 funding round from investors including Blueprint Medicines. Lengo Therapeutics offers products and services including Avapritinib, Elenestinib, and BLU-808. Lengo Therapeutics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Blueprint Medicines Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$15 M (USD)
in 1 rounds
-
Latest Funding Round
$15 M (USD), Series A
Jun 01, 2020
- Investors
-
Employee Count
Employee Count
-
Acquired by
Blueprint Medicines
(Nov 29, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lengo Therapeutics
Lengo Therapeutics offers a comprehensive portfolio of products and services, including Avapritinib, Elenestinib, and BLU-808. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for systemic mastocytosis and gastrointestinal stromal tumors.
Development program for advanced and indolent systemic mastocytosis.
Planned for chronic urticaria and other mast cell-mediated diseases.
Unlock access to complete
Unlock access to complete
Leadership Team
55 people
Operations Team
13 people
Human Resources and Administration
12 people
Software Development Team
12 people
Senior Team
12 people
Sales and Marketing
10 people
Area Team
10 people
Product Management Team
9 people
Unlock access to complete
Funding Insights of Lengo Therapeutics
Lengo Therapeutics has successfully raised a total of $15M through 1 strategic funding round. The most recent funding activity was a Series A round of $15 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $15.0M
-
First Round
First Round
(01 Jun 2020)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Series A - Lengo Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lengo Therapeutics
Lengo Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Blueprint Medicines. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Selective kinase inhibitors are developed for genomically defined cancers.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lengo Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Lengo Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lengo Therapeutics Comparisons
Competitors of Lengo Therapeutics
Lengo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lengo Therapeutics
Frequently Asked Questions about Lengo Therapeutics
When was Lengo Therapeutics founded?
Lengo Therapeutics was founded in 2020.
Where is Lengo Therapeutics located?
Lengo Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Lengo Therapeutics?
Enoch Kariuki is the current CEO of Lengo Therapeutics.
Is Lengo Therapeutics a funded company?
Lengo Therapeutics is a funded company, having raised a total of $15M across 1 funding round to date. The company's 1st funding round was a Series A of $15M, raised on Jun 01, 2020.
What does Lengo Therapeutics do?
Lengo Therapeutics was founded in 2020 and is based in San Diego, United States. Precision medicines for oncology are developed by the company within the biotechnology sector. Kinase biology and covalent drug-target technology are employed to identify mutations in various cancers. Therapeutics aimed at treating multiple solid tumors are created through these methods. Operations focus on advancing targeted treatments for oncology applications.
Who are the top competitors of Lengo Therapeutics?
Lengo Therapeutics's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
What products or services does Lengo Therapeutics offer?
Lengo Therapeutics offers Avapritinib, Elenestinib, and BLU-808.
Who are Lengo Therapeutics's investors?
Lengo Therapeutics has 1 investor. Key investors include Blueprint Medicines.